Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib versus ocrelizumab in primary progressive multiple sclerosis
2019-003919-53Phase 3Active
- Sponsor
- Roche
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) comparing Fenebrutinib arm with Ocrelizumab arm (2 arms). Primary endpoint: Time to onset of cCDP12. Started Jul 2020; status: active.
02
Drugs
fenebrutinibocrelizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2019-003919-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003919-53.